Cargando…
Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as candidates for environmental triggers but, giv...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450860/ https://www.ncbi.nlm.nih.gov/pubmed/30675626 http://dx.doi.org/10.1007/s00125-019-4811-7 |
_version_ | 1783409081276432384 |
---|---|
author | Dunne, Jessica L. Richardson, Sarah J. Atkinson, Mark A. Craig, Maria E. Dahl-Jørgensen, Knut Flodström-Tullberg, Malin Hyöty, Heikki Insel, Richard A. Lernmark, Åke Lloyd, Richard E. Morgan, Noel G. Pugliese, Alberto |
author_facet | Dunne, Jessica L. Richardson, Sarah J. Atkinson, Mark A. Craig, Maria E. Dahl-Jørgensen, Knut Flodström-Tullberg, Malin Hyöty, Heikki Insel, Richard A. Lernmark, Åke Lloyd, Richard E. Morgan, Noel G. Pugliese, Alberto |
author_sort | Dunne, Jessica L. |
collection | PubMed |
description | In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as candidates for environmental triggers but, given the lack of evidence for an acute, widespread, cytopathic effect in the pancreas in type 1 diabetes or for a closely related temporal association of diabetes onset with such infections, a role for viruses in type 1 diabetes remains unproven. Moreover, viruses have rarely been isolated from the pancreas of individuals with type 1 diabetes, mainly (but not solely) due to the inaccessibility of the organ. Here, we review past and recent literature to evaluate the proposals that chronic, recurrent and, possibly, persistent enteroviral infections occur in pancreatic beta cells in type 1 diabetes. We also explore whether these infections may be sustained by different virus strains over time and whether multiple viral hits can occur during the natural history of type 1 diabetes. We emphasise that only a minority of beta cells appear to be infected at any given time and that enteroviruses may become replication defective, which could explain why they have been isolated from the pancreas only rarely. We argue that enteroviral infection of beta cells largely depends on the host innate and adaptive immune responses, including innate responses mounted by beta cells. Thus, we propose that viruses could play a role in type 1 diabetes on multiple levels, including in the triggering and chronic stimulation of autoimmunity and in the generation of inflammation and the promotion of beta cell dysfunction and stress, each of which might then contribute to autoimmunity, as part of a vicious circle. We conclude that studies into the effects of vaccinations and/or antiviral drugs (some of which are currently on-going) is the only means by which the role of viruses in type 1 diabetes can be finally proven or disproven. |
format | Online Article Text |
id | pubmed-6450860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-64508602019-04-17 Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes Dunne, Jessica L. Richardson, Sarah J. Atkinson, Mark A. Craig, Maria E. Dahl-Jørgensen, Knut Flodström-Tullberg, Malin Hyöty, Heikki Insel, Richard A. Lernmark, Åke Lloyd, Richard E. Morgan, Noel G. Pugliese, Alberto Diabetologia For Debate In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as candidates for environmental triggers but, given the lack of evidence for an acute, widespread, cytopathic effect in the pancreas in type 1 diabetes or for a closely related temporal association of diabetes onset with such infections, a role for viruses in type 1 diabetes remains unproven. Moreover, viruses have rarely been isolated from the pancreas of individuals with type 1 diabetes, mainly (but not solely) due to the inaccessibility of the organ. Here, we review past and recent literature to evaluate the proposals that chronic, recurrent and, possibly, persistent enteroviral infections occur in pancreatic beta cells in type 1 diabetes. We also explore whether these infections may be sustained by different virus strains over time and whether multiple viral hits can occur during the natural history of type 1 diabetes. We emphasise that only a minority of beta cells appear to be infected at any given time and that enteroviruses may become replication defective, which could explain why they have been isolated from the pancreas only rarely. We argue that enteroviral infection of beta cells largely depends on the host innate and adaptive immune responses, including innate responses mounted by beta cells. Thus, we propose that viruses could play a role in type 1 diabetes on multiple levels, including in the triggering and chronic stimulation of autoimmunity and in the generation of inflammation and the promotion of beta cell dysfunction and stress, each of which might then contribute to autoimmunity, as part of a vicious circle. We conclude that studies into the effects of vaccinations and/or antiviral drugs (some of which are currently on-going) is the only means by which the role of viruses in type 1 diabetes can be finally proven or disproven. Springer Berlin Heidelberg 2019-01-23 2019 /pmc/articles/PMC6450860/ /pubmed/30675626 http://dx.doi.org/10.1007/s00125-019-4811-7 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | For Debate Dunne, Jessica L. Richardson, Sarah J. Atkinson, Mark A. Craig, Maria E. Dahl-Jørgensen, Knut Flodström-Tullberg, Malin Hyöty, Heikki Insel, Richard A. Lernmark, Åke Lloyd, Richard E. Morgan, Noel G. Pugliese, Alberto Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes |
title | Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes |
title_full | Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes |
title_fullStr | Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes |
title_full_unstemmed | Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes |
title_short | Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes |
title_sort | rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes |
topic | For Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450860/ https://www.ncbi.nlm.nih.gov/pubmed/30675626 http://dx.doi.org/10.1007/s00125-019-4811-7 |
work_keys_str_mv | AT dunnejessical rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT richardsonsarahj rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT atkinsonmarka rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT craigmariae rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT dahljørgensenknut rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT flodstromtullbergmalin rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT hyotyheikki rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT inselricharda rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT lernmarkake rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT lloydricharde rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT morgannoelg rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes AT pugliesealberto rationaleforenteroviralvaccinationandantiviraltherapiesinhumantype1diabetes |